Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.

OBJECTIVE In this article, we review the role of imaging in cancer of unknown primary site (CUP) diagnosis and management and the utility of immunohistochemistry, serum tumor markers, and molecular profiling in the optimized care of CUP patients. CONCLUSION With advances in imaging, pathology, and molecular medicine, the diagnosis and management of CUP have evolved into more personalized and site-specific therapies. A multidisciplinary integrated approach among oncologists, pathologists, and radiologists is extremely important.

[1]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[2]  J. Hainsworth,et al.  Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. , 1986, Annals of internal medicine.

[3]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[4]  C. White,et al.  Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? , 1997, AJR. American journal of roentgenology.

[5]  Greg L Perkins,et al.  Serum tumor markers. , 2003, American family physician.

[6]  J. Platt,et al.  Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. , 2003, AJR. American journal of roentgenology.

[7]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[8]  A. Gadducci,et al.  Serum tumor markers in the management of ovarian, endometrial and cervical cancer. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  R. Lenzi,et al.  Diagnostic strategies for unknown primary cancer , 2004, Cancer.

[10]  M. Schnall,et al.  Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. , 2004, Clinical breast cancer.

[11]  V. Ambrosini,et al.  18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin , 2006, La radiologia medica.

[12]  S. Park,et al.  Bloodborne metastatic tumors to the gastrointestinal tract: CT findings with clinicopathologic correlation. , 2006, AJR. American journal of roentgenology.

[13]  N. Pavlidis,et al.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray. , 2007, European journal of cancer.

[14]  J. Mackey,et al.  The role of 2‐deoxy‐2‐[F‐18]fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site , 2007, Cancer.

[15]  J. Hainsworth,et al.  Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Duraker,et al.  CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice , 2007, Journal of surgical oncology.

[17]  Kenneth R Hess,et al.  Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jian-hua Yin,et al.  Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. , 2008, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[19]  N. Pavlidis,et al.  Carcinoma of Unknown Primary (CUP) , 2014 .

[20]  J. Hainsworth,et al.  Treatment for patients with unknown primary cancer and favorable prognostic factors. , 2009, Seminars in oncology.

[21]  K. Oien,et al.  Pathologic evaluation of unknown primary cancer. , 2009, Seminars in oncology.

[22]  Jeong Hyun Lee,et al.  Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. , 2009, Oral oncology.

[23]  G. Varadhachary,et al.  Overview of patient management and future directions in unknown primary carcinoma. , 2009, Seminars in oncology.

[24]  J. Hainsworth,et al.  Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. , 2009, The oncologist.

[25]  W. E. Jordan,et al.  Cancer of unknown primary site. , 2010, Seminars in oncology.

[26]  Byung Ihn Choi,et al.  Assessment of the treatment response of HCC , 2011, Abdominal Imaging.

[27]  R. Molina,et al.  Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site , 2012, Tumor Biology.

[28]  J. Nesland,et al.  Fine needle aspirations in oncology. , 2011, Arkhiv patologii.

[29]  G. Varadhachary.  Carcinoma of unknown primary: focused evaluation. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[30]  D. Ettinger,et al.  NCCN Clinical Practice Guidelines Occult primary. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  G. Psychogios,et al.  Carcinoma of unknown primary in the head and neck: Comparison between positron emission tomography (PET) and PET/CT , 2011, Head & neck.

[32]  M. Erlander,et al.  Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  N. Pavlidis,et al.  Cancer of unknown primary site , 2012, The Lancet.

[34]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[35]  M. B. Taylor,et al.  Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. , 2012, The British journal of radiology.

[36]  E. Genden,et al.  Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches , 2013, Head & neck.

[37]  N. Pavlidis,et al.  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.